Skip to content

Study · Observational study · n = 4,042 · 2016

4 results

Teriparatide in patients with osteoporosis and type 2 diabetes.

Schwartz AV, Pavo I, Alam J, Disch DP, Schuster D, Harris JM, Krege JH

Bone1 Jul 2016Cited by 67 (Europe PMC)

PMID27374026 (opens in a new tab)DOI10.1016/j.bone.2016.06.017 (opens in a new tab)PepBankPUB-27374026
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In osteoporosis with and without diabetes, back pain severity decreased during teriparatide treatment.

    In plain wordsIn osteoporosis with and without diabetes, teriparatide treatment was linked to less back pain than at baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBack pain severity
    Study

    n = 4,042

    Comparator
    Baseline
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 μg/day · subcutaneous · up to 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Back pain severity decreased in both groups.
    2 context sentences
    Summary · context
    Post hoc analyses of the DANCE observational study compared T2D patients and patients without diabetes to assess the effect of teriparatide, an osteoanabolic therapy on skeletal outcomes and safety.
    Summary · context
    Patients included ambulatory men and women with osteoporosis receiving teriparatide 20μg/day SQ up to 24months followed by observation up to 24months.
  2. 02HumanObservational studySafety outcome

    In osteoporosis with and without diabetes, teriparatide was well tolerated without new safety findings.

    In plain wordsIn osteoporosis with and without diabetes, teriparatide was well tolerated, with no new safety findings.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableTolerability
    Study

    n = 4,042

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 μg/day · subcutaneous · up to 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Teriparatide was well tolerated without new safety findings.
    2 context sentences
    Summary · context
    Post hoc analyses of the DANCE observational study compared T2D patients and patients without diabetes to assess the effect of teriparatide, an osteoanabolic therapy on skeletal outcomes and safety.
    Summary · context
    Patients included ambulatory men and women with osteoporosis receiving teriparatide 20μg/day SQ up to 24months followed by observation up to 24months.
  3. 03HumanObservational studyEfficacy outcome

    In osteoporosis without diabetes, nonvertebral fracture incidence during teriparatide fell from 3.2 to 1.8 per 100 patient-years after the first 6 months of treatment.

    In plain wordsIn osteoporosis without diabetes, later teriparatide treatment was linked to fewer fractures than the first treatment period.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseNonvertebral fractures without diabetes
    Study

    n = 3,751

    Comparator
    0-6 months of teriparatide treatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · subcutaneous · up to 24 monthsAs given in this study (human).

    Measurements

    Nonvertebral fracture incidence
    3.2 per 100 patient-years
    without diabetes, 0-6 months of teriparatide
    Nonvertebral fracture incidence
    1.8 per 100 patient-years
    without diabetes, 6 months to treatment end
    Incidence relative to 0-6 months
    57 % of baseline
    without diabetes; 95% CI 39-83%

    Source sentences

    Summary
    during similar periods, for patients without diabetes, fracture incidence was 3.2 and 1.8 (57% of baseline, 95% CI 39-83%).
    2 context sentences
    Summary · context
    Post hoc analyses of the DANCE observational study compared T2D patients and patients without diabetes to assess the effect of teriparatide, an osteoanabolic therapy on skeletal outcomes and safety.
    Summary · context
    Patients included ambulatory men and women with osteoporosis receiving teriparatide 20μg/day SQ up to 24months followed by observation up to 24months.
  4. 04HumanObservational studyEfficacy outcome

    In osteoporosis with T2D, nonvertebral fracture incidence during teriparatide fell from 3.5 to 1.6 per 100 patient-years after the first 6 months of treatment.

    In plain wordsIn osteoporosis with diabetes, later teriparatide treatment was linked to fewer fractures than the first treatment period.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseNonvertebral fractures in T2D
    Study

    n = 291

    Comparator
    0-6 months of teriparatide treatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · subcutaneous · up to 24 monthsAs given in this study (human).

    Measurements

    Nonvertebral fracture incidence
    3.5 per 100 patient-years
    T2D, 0-6 months of teriparatide
    Nonvertebral fracture incidence
    1.6 per 100 patient-years
    T2D, 6 months to treatment end
    Incidence relative to 0-6 months
    47 % of baseline
    T2D; 95% CI 12-187%

    Source sentences

    Summary
    For T2D patients, fracture incidence was 3.5 per 100 patient-years during 0-6months treatment, and 1.6 during 6months to treatment end (47% of baseline, 95% CI 12-187%);
    2 context sentences
    Summary · context
    Post hoc analyses of the DANCE observational study compared T2D patients and patients without diabetes to assess the effect of teriparatide, an osteoanabolic therapy on skeletal outcomes and safety.
    Summary · context
    Patients included ambulatory men and women with osteoporosis receiving teriparatide 20μg/day SQ up to 24months followed by observation up to 24months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.